A Cost Minimization and Budget Impact Analysis of an Eculizumab Biosimilar, ABP 959, From the Spanish Healthcare Perspective
Author(s)
Fiston Vuvu, MSc1, Joshua Porter, BSc, MSc2, Marta Sacrest, BSc3, Matthew Arden, BSc4, Alex Hirst, BSc, MSc4, Seun Lashilola, BSc4.
1Amgen Inc, California, CA, USA, 2Amgen (Europe), Zug, Switzerland, 3Amgen (Spain), Barcelona, Spain, 4Adelphi Values, London, United Kingdom.
1Amgen Inc, California, CA, USA, 2Amgen (Europe), Zug, Switzerland, 3Amgen (Spain), Barcelona, Spain, 4Adelphi Values, London, United Kingdom.
OBJECTIVES: To estimate the economic consequences of adopting ABP 959, an eculizumab biosimilar, for treating paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS).
METHODS: Cost minimization and budget impact analyses (CMA and BIA) were developed from the Spanish healthcare perspective, with a five-year time horizon. The CMA estimated annual costs of treatment, per patient, with originator eculizumab, ABP 959, and ravulizumab - with a maintenance regimen of once every two weeks for eculizumab (originator and ABP 959) and once every eight weeks for ravulizumab. The BIA estimated the budgetary impact following ABP 959 adoption into the current treatment mix (originator eculizumab and ravulizumab). Both analyses included published epidemiological inputs, drug acquisition costs (using list prices), and administration costs (using published literature). ABP 959’s market uptake was based on assumptions. CMA results were averages weighted by the proportion of patients with each indication; BIA results considered both indications together.
RESULTS: The CMA showed the estimated cost per patient is substantially lower with ABP 959 compared with originator eculizumab and ravulizumab. Compared to originator eculizumab, the estimated saving is €106,595/year (~30%) in year 1 and €103,559/year (~30%) subsequently; compared to ravulizumab, savings are €97,371/year (~28%) in year 1 and €78,505 (~24%) subsequently. Savings are driven by a substantial reduction in acquisition costs. Furthermore, there is only a small administration cost increase compared to ravulizumab: ~€3,000/year. Annual estimated budget savings range between €1.8M (Year 1) and €53M (Year 5), with cumulative savings of €162.6M at Year 5.
CONCLUSIONS: The CMA and BIA both demonstrated substantial estimated cost savings with ABP 959 compared with originator eculizumab and ravulizumab. The savings in drug acquisition costs offset the higher administration costs from more frequent administrations of ABP 959 compared with ravulizumab. These results support the rapid adoption of ABP 959 in treating PNH and aHUS.
METHODS: Cost minimization and budget impact analyses (CMA and BIA) were developed from the Spanish healthcare perspective, with a five-year time horizon. The CMA estimated annual costs of treatment, per patient, with originator eculizumab, ABP 959, and ravulizumab - with a maintenance regimen of once every two weeks for eculizumab (originator and ABP 959) and once every eight weeks for ravulizumab. The BIA estimated the budgetary impact following ABP 959 adoption into the current treatment mix (originator eculizumab and ravulizumab). Both analyses included published epidemiological inputs, drug acquisition costs (using list prices), and administration costs (using published literature). ABP 959’s market uptake was based on assumptions. CMA results were averages weighted by the proportion of patients with each indication; BIA results considered both indications together.
RESULTS: The CMA showed the estimated cost per patient is substantially lower with ABP 959 compared with originator eculizumab and ravulizumab. Compared to originator eculizumab, the estimated saving is €106,595/year (~30%) in year 1 and €103,559/year (~30%) subsequently; compared to ravulizumab, savings are €97,371/year (~28%) in year 1 and €78,505 (~24%) subsequently. Savings are driven by a substantial reduction in acquisition costs. Furthermore, there is only a small administration cost increase compared to ravulizumab: ~€3,000/year. Annual estimated budget savings range between €1.8M (Year 1) and €53M (Year 5), with cumulative savings of €162.6M at Year 5.
CONCLUSIONS: The CMA and BIA both demonstrated substantial estimated cost savings with ABP 959 compared with originator eculizumab and ravulizumab. The savings in drug acquisition costs offset the higher administration costs from more frequent administrations of ABP 959 compared with ravulizumab. These results support the rapid adoption of ABP 959 in treating PNH and aHUS.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE304
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Rare & Orphan Diseases